Glioma Pipeline Appears Promising With 180+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
Discover the latest drugs and treatment options in the Glioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Glioma Pipeline Outlook
Key Takeaways from the Glioma Pipeline Report
In July 2025, Eli Lilly and Company announced a study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.
In July 2025, Istari Oncology Inc. announced a Phase 2 study of lerapolturev, an oncolytic polio/rhinovirus recombinant, in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma. The objective of this study is to investigate the safety and efficacy (anti-tumor response and survival) of lerapolturev in recurrent WHO grade IV malignant glioma.
In July 2025, Incyte Corporation conducted a study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.
In July 2025, Nuvation Bio Inc. organized a 2-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.
DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.
The leading Glioma Companies such as CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others.
Promising Glioma Pipeline Therapies such as DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.
Stay ahead with the most recent pipeline outlook for Glioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Glioma Treatment Drugs
Glioma Emerging Drugs Profile
AV-GBM-1: Aivita Biomedical, Inc.
AV-GBM-1 is an innovative immunotherapy developed by AIVITA Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells that are loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient's unique cancer profile. Currently, the drug is in phase III stage of its clinical trial for the treatment of Glioma.
DB 107: Denovo BioPharma
Denovo BioPharma's DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.
MDNA55: Medicenna Therapeutics, Inc.
MDNA55 is a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.
Abemaciclib: Eli Lilly and Company
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
NMS-03305293: Nerviano Medical Sciences
NMS-293 is a second generation PARP inhibitor that differentiates from other approved or advanced molecules in its unique selectivity for PARP1 vs. PARP2 enzymes and low DNA trapping activity, both features potentially linked to lower hematological toxicity and higher potential for combination with DNA damaging agents in a wide range of tumors, covering high unmet medical needs. It also has a superior ability to penetrate the blood-brain barrier, a very important feature supporting its utilization in CNS tumors and brain metastases. The drug has shown high anti-tumor activity as single agent in BRCA mutated preclinical tumor models and synergy and tolerability in combination with chemotherapy. Based on the findings, NMS-293 is currently in clinical developmental Phase II in combination with temozolomide in recurrent glioblastoma.
CAN-3110: Candel Therapeutics
CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent HGG. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioma.
MB-101: Mustang Bio
MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. Currently, the drug is in Phase I stage of clinical trial for the treatment of Glioma.
The Glioma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment.
Glioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market
Explore groundbreaking therapies and clinical trials in the Glioma Pipeline. Access DelveInsight's detailed report now! @ New Glioma Drugs
Glioma Companies
CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others.
Glioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Glioma Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Unveil the future of Glioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Glioma Market Drivers and Barriers
Scope of the Glioma Pipeline Report
Coverage- Global
Glioma Companies- CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others.
Glioma Pipeline Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.
Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Glioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Glioma Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Glioma Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Glioma Disease– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
AV-GBM-1: Aivita Biomedical, Inc.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
DB 107: Denovo BioPharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MB-101: Mustang Bio
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Glioma Disease Key Companies
Glioma Disease Key Products
Glioma Disease- Unmet Needs
Glioma Disease- Market Drivers and Barriers
Glioma Disease- Future Perspectives and Conclusion
Glioma Disease Analyst Views
Glioma Disease Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glioma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 minutes ago
- Globe and Mail
American Express Declares Dividend on Series D Preferred Stock
The Board of Directors of American Express Company (NYSE: AXP) declared a quarterly dividend on the Company's 3.550% Fixed Rate Reset Noncumulative Preferred Shares, Series D, of $9,072.22 per share (which is equivalent to $9.07222 per related Depositary Share). The dividend is payable on September 15, 2025, to shareholders of record on September 1, 2025. ABOUT AMERICAN EXPRESS American Express (NYSE: AXP) is a global payments and premium lifestyle brand powered by technology. Our colleagues around the world back our customers with differentiated products, services and experiences that enrich lives and build business success. Founded in 1850 and headquartered in New York, American Express' brand is built on trust, security, and service, and a rich history of delivering innovation and Membership value for our customers. With over a hundred million merchant locations across our global network, we seek to provide the world's best customer experience every day to a broad range of consumers, small and medium-sized businesses, and large corporations. For more information about American Express, visit and
Globe and Mail
17 minutes ago
- Globe and Mail
At Home Nursing Care Brings Top-Tier In-Home Caregivers to San Diego, CA
At Home Nursing Care proudly delivers top-tier in-home caregivers in San Diego, CA, offering families compassionate, personalized support tailored to their loved ones' unique needs. Led by founder Lauren Reynolds, the agency upholds the highest standards in caregiver vetting, training, and care delivery—ensuring dignity, independence, and peace of mind for every client. Learn more at San Diego, CA - At Home Nursing, a leading provider of home care services, today reaffirmed its ongoing mission to supply the most qualified and compassionate in-home caregivers in the San Diego area. Under the guidance of Lauren Reynolds, the agency continues to set the standard for excellence, ensuring that families have a trusted partner for the well-being of their loved ones. This sustained focus addresses the growing need for dependable and professional care that allows individuals to thrive in the comfort and familiarity of their own homes. As the population ages and more families seek alternatives to institutional care, the demand for high-quality home care has never been greater. Navigating this landscape can be overwhelming, with families often facing the challenge of finding caregivers who are not only skilled but also genuinely compassionate and reliable. At Home Nursing directly confronts this challenge by dedicating its resources to recruiting, training, and retaining the very best care professionals, thereby providing a solution that families can count on. One of the primary benefits of partnering with At Home Nursing is the delivery of highly personalized care plans. The agency recognizes that every individual has unique needs and preferences. Therefore, they work closely with clients and their families to develop a customized regimen of care, whether it involves assistance with daily activities, medication management, or more specialized support. This tailored approach ensures that each client receives the precise level of care required to maintain their independence and enhance their quality of life. Furthermore, the agency provides an unparalleled level of trust and security. Families seeking an in-home caregiver in San Diego can rest assured knowing that every professional from At Home Nursing has undergone a rigorous vetting process, including comprehensive background checks, credential verification, and in-depth interviews. This commitment to hiring only the most qualified individuals means that clients are cared for by professionals who are not only skilled but also dedicated to providing respectful, dignified, and empathetic support. "Our goal has always been more than just providing a service; it's about becoming a trusted extension of the family," says Lauren Reynolds, founder of At Home Nursing Care. "We understand the immense trust placed in us when we are invited into a home. That's why we are unwavering in our mission to supply the most compassionate and skilled caregivers, ensuring every client receives the dignified and respectful care they deserve." As At Home Nursing moves forward, its core mission remains the essential driver of its operations. By focusing on the quality of its caregivers and the specific needs of each client, the agency solidifies its reputation as the premier source for home care in San Diego, CA. Families in need of dedicated and professional care are encouraged to contact the agency to learn more about its comprehensive services. For more information about At Home Nursing Care and their in-home caregivers in San Diego, CA, please visit their website at About At Home Nursing Care: Founded on the belief that everyone deserves dignified, high-quality care at home, At Home Nursing has become a trusted name in home care in San Diego, CA. The company rigorously screens and trains its caregivers, emphasizing empathy, reliability, and skill. Services range from personal care and meal preparation to specialized medical support, all designed to enhance clients' quality of life. Media Contact Company Name: At Home Nursing Care Contact Person: Lauren Reynolds Email: Send Email Phone: +1 760 634 8000 Address: 531 Encinitas Blvd #120 City: Encinitas State: CA Country: United States Website:
Globe and Mail
17 minutes ago
- Globe and Mail
US stocks edge up to another record as GM and others show how tariffs are impacting them
NEW YORK (AP) — US stocks drifted to another record following some mixed profit reports, as General Motors and other big U.S. companies give updates on how much President Donald Trump's tariffs are hurting or helping them. The S&P 500 rose 0.1% Tuesday to beat the all-time high it set a day earlier. The Dow Jones Industrial Average added 0.4%, and the Nasdaq composite fell 0.4% from its record. General Motors dropped 8.1% despite reporting a stronger profit than expected, as it still sees a $4 billion to $5 billion hit this year because of tariffs. Homebuilders soared following their better-than-forecast profit reports. THIS IS A BREAKING NEWS UPDATE. AP's earlier story follows below. NEW YORK (AP) — Wall Street is hanging around its records on Tuesday following some mixed profit reports, as General Motors and other big U.S. companies give updates on how much President Donald Trump's tariffs are hurting or helping them. The S&P 500 was 0.1% higher in late trading and on track to squeak to another all-time high. The Dow Jones Industrial Average was up 164 points, or 0.4%, with an hour remaining in trading, and the Nasdaq composite was down 0.2% after setting its own record. General Motors dropped 7.5% despite reporting a stronger profit for the spring than analysts expected. The automaker said it's still expecting a $4 billion to $5 billion hit to its results over 2025 because of tariffs and that it hopes to mitigate 30% of that. GM also said it will feel more pain because of tariffs in the current quarter than it did during the spring. That helped to offset big gains for some homebuilders after they reported stronger profits for the spring than Wall Street had forecast. D.R. Horton rallied 16.5%, and PulteGroup jumped 11.4%. That was even as both companies said homebuyers are continuing to deal with challenging conditions, including higher mortgage rates and an uncertain economy. So far, the U.S. economy seems to be powering through all the uncertainty created by Trump's on-and-off tariffs. Many of Trump's stiff proposed taxes on imports are currently on pause, and the next big deadline is Aug. 1. Talks are underway on possible trade deals with other countries that could lower the proposed tariffs before they kick in. Companies are already feeling effects. Genuine Parts, the Atlanta-based company that sells auto and industrial replacement parts around the world, trimmed its profit forecast for the full year in order to incorporate 'all U.S. tariffs currently in effect,' along with its updated expectations for business conditions in the second half of the year. Its stock rose 6.5% after it reported a stronger profit for the latest quarter than analysts expected. RTX fell 1.2% after cutting its forecast for profit in 2025 but also raising its forecast for revenue. It made the changes to incorporate what CEO Chris Calio called 'our current assessment of the impact of tariffs,' along with other changes anticipated from Washington's recent approval of big tax changes. Coca-Cola slipped 0.7% even though it delivered a stronger profit than forecast. Its revenue for the quarter only edged past analysts' expectations, and it said that higher prices that it charged helped offset sales of fewer cases during the spring. Opendoor Technologies, a company that's caught interest among investors looking for the next 'meme stock' that could rise regardless of how its profits are doing, lost momentum and dropped 10.7% to $2.86. It had climbed as high as $3.99 in the morning, more than quintuple its price of 78 cents from just two Fridays ago. In the bond market, Treasury yields sank as traders continue to expect the Federal Reserve to wait until September at the earliest to resume cutting interest rates. Fed Chair Jerome Powell has been insisting he wants to see more data about how Trump's tariffs are affecting inflation and the economy before the Fed makes its next move. That's despite often angry criticism from Trump, who has been lobbying for more cuts to rates to happen sooner. The yield on the 10-year Treasury eased to 4.33% from 4.38% late Monday. In overseas markets, Japan's benchmark surged and then fell back as it reopened from a holiday Monday following the ruling coalition's loss of its upper house majority in Sunday's election. The Nikkei 225 shed 0.1%. Analysts said the market initially climbed on relief that Prime Minister Shigeru Ishiba vowed to stay in office despite a loss for his ruling coalition in an upper-house election Sunday. But the results have only added to political uncertainty and left his government without the heft needed to push through legislation. A breakthrough in trade talks with the U.S. might win Ishiba a reprieve, but so far there's been scant sign of progress in negotiating away the threat of higher tariffs on Japan's exports to the U.S. beginning Aug. 1. Indexes were mixed elsewhere in Asia and Europe.
